Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients

SIMPLE SUMMARY: Ongoing clinical trials are recently investigating the efficacy of second-line EGFR inhibitors in initially RAS mutant metastatic colorectal cancer patients who convert to RAS wild-type in plasma, as assessed by circulating tumor DNA (ctDNA) analysis. To this purpose, discriminating...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicolazzo, Chiara, Barault, Ludovic, Caponnetto, Salvatore, Macagno, Marco, De Renzi, Gianluigi, Gradilone, Angela, Belardinilli, Francesca, Cortesi, Enrico, Di Nicolantonio, Federica, Gazzaniga, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761880/
https://www.ncbi.nlm.nih.gov/pubmed/33291569
http://dx.doi.org/10.3390/cancers12123633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761880/
https://www.ncbi.nlm.nih.gov/pubmed/33291569
http://dx.doi.org/10.3390/cancers12123633

Ejemplares similares